Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab

被引：0
|
作者：
Kyi, Chrisann
Van Dongen, Marloes
Rottey, Sylvie
Bermejo, Ignacio Melero
Mittag, Diana
Gouveia, Dane
Bol, Kees
Yan, Chris
Joe, Andrew K.
Laus, Gianluca
Moreno, Victor
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Netherlands Canc Inst, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[3] Ghent Univ Hosp, Ghent, Belgium
[4] Univ Navarra Clin, Pamplona, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Univ Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Prenen, H.
    Kyi, C.
    Van Lancker, G.
    Patel, S. P.
    Mittag, D.
    Weaver, A.
    Bol, K.
    Stalbovskaya, V.
    Pulini, J.
    Zhou, G.
    Dong, Z.
    Asatiani, E.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436
  • [2] Identification and characterization of MCLA-145 (CD137 x PD-L1): a bispecific antibody that requires PD-L1 binding to activate CD137
    Plyte, Simon
    Geuijen, Cecile
    de Kruif, John
    van Loo, Pieter Fokko
    Tacken, Paul
    Zondag-vander Zande, Vanessa
    Klooster, Rinse
    van Maaden, Hans
    Rovers, Erik
    Engels, Steef
    Franzen, Floris
    Basmeleh, Abdul
    Bartelink, Willem
    Throsby, Mark
    Mayes, Patrick
    Nastri, Horacio
    Stewart, Shaun
    Zhou, Jing
    Wang, Steve
    Huang, Chen-yen
    Codamine, Thomas
    Kularni, Ashwini
    bin Lui, Yao
    Mondal, Arpita
    Hall, Leslie
    Kim, Soeon
    Martinez, Marina
    O'brien, Shaun
    Moon, Edmund
    Albelda, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] MCLA-145 IS A BISPECIFIC IGG1 ANTIBODY THAT INHIBITS PD-1/PD-L1 SIGNALING WHILE SIMULTANEOUSLY ACTIVATING CD137 SIGNALING ON T CELLS
    Tacken, Paul
    Wang, Liang-chuan
    Klooster, Rinse
    Van Loo, Pieter Fokko
    Zhou, Jing
    Mondal, Arpita
    Liu, Yao-Bin
    Kramer, Arjen
    Condamine, Thomas
    Volgina, Alla
    Hendriks, Linda
    van der Maaden, Hans
    Rovers, Eric
    Engels, Steef
    Fransen, Floris
    den Blanken-Smit, Renate
    Zondag-van der Zande, Vanessa
    Basmeleh, Abdul
    Bartelink, Willem
    Kulkarni, Ashwini
    Marissen, Wilfred
    Huang, Cheng-Yen
    Hall, Leslie
    Harvey, Shane
    Kanellopoulou, Chrysi
    Stewart, Shaun
    Nastri, Horacio
    Bakker, Lex
    Logtenberg, Ton
    Plyte, Simon
    Mayes, Patrick
    Throsby, Mark
    Geuijen, Cecile
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A491 - A491
  • [4] Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody
    Lakins, M. A.
    Munoz-Olaya, J.
    Jones, D.
    Giambalvo, R.
    Hall, C.
    Knudsen, A.
    Soler, N. Masque
    Pechouckova, S.
    Goodman, E.
    Gradinaru, C.
    Koers, A.
    Marshall, S.
    Wydro, M.
    Wollerton, F.
    Batey, S.
    Gliddon, D.
    Davies, M.
    Morrow, M.
    Tuna, M.
    Brewis, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] MCLA-145 (CD137XPD-L1): A POTENT CD137 AGONIST AND IMMUNE CHECKPOINT INHIBITOR THAT THAT DOES NOT SHOW SIGNS OF PERIPHERAL TOXICITY
    Bol, Kees
    Marissen, Wilfred
    Elaissais-Schaap, Jeroen
    Tacken, Paul
    Engels, Steef
    Wang, Liang-Chuan
    Mondal, Arpita
    Throsby, Mark
    Roberts, Alan
    Mayes, Patrick
    Geuijen, Cecile
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A487 - A487
  • [6] A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies
    Garralda, E.
    Melero, I.
    de Velasco, G.
    Moreno, V.
    Oberoi, H. K.
    Shepherd, C.
    Jones, D.
    Lakins, M. A.
    Hurley, P.
    Khambhatwala, S.
    Long, D.
    Kayitalire, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1454 - S1454
  • [7] A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Huang, Po-Lin
    Kan, Hung-Tsai
    Hsu, Ching-Hsuan
    Hsieh, Hsin-Ta
    Cheng, Wan-Chien
    Huang, Ren-Yeong
    You, Jhong-Jhe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [8] MCLA-145, AN ANTI CD137xPD-L1 BISPECIFIC ANTIBODY, INDUCES T CELL ACTIVATION AND PROLIFERATION IN EX VIVO MODELS OF HEPATOCELLULAR CARCINOMA
    Desai, Jyaysi
    Noordam, Lissane
    Boor, Patrick
    Bouzid, Rachid
    Mittag, Diana
    Tacken, Paul
    van Bueren, Jeroen Lammerts
    Guijen, Cecile
    Kwekkeboom, Jaap
    Sprengers, Dave
    Buschow, Sonja
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A920 - A920
  • [9] Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Po-Lin Huang
    Hung-Tsai Kan
    Ching-Hsuan Hsu
    Hsin-Ta Hsieh
    Wan-Chien Cheng
    Ren-Yeong Huang
    Jhong-Jhe You
    Journal of Translational Medicine, 21
  • [10] Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.
    Wang, Jie
    Sun, Yuping
    Chu, Qian
    Duan, Jianchun
    Wan, Rui
    Wang, Zhijie
    Zhao, Jun
    Li, Haoyuan
    Guo, Yingmei
    Chen, Yuling
    Wang, Yan
    CANCER RESEARCH, 2022, 82 (12)
12345